ArticleBreast (Edinburgh, Scotland)2026
Incidence of lymphomas in a nationwide prospective cohort study of breast-implanted women.
Article in Breast (Edinburgh, Scotland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe true incidence of Breast Implant Associated-Anaplastic Large Cell Lymphoma (BIA-ALCL), a rare cancer associated with textured breast implants, remains uncertain due to limitations of implant exposure data and long-term follow-up. Concerns regarding other implant-associated malignancies are growing. This study aimed to determine the incidence of BIA-ALCL, non-BIA-ALCL lymphoma, and Breast Implant Associated-Squamous Cell Carcinoma (BIA-SCC).
methods10,339 women with a first-time breast implantation during 1998-2011 were identified in the nationwide prospective Danish Registry for Plastic Surgery of the Breast (DPB). Linkage to national health registries provided outcome data. Incidence of non-BIA-ALCL was compared with the incidence in 1) 3486 women with breast reduction or mastopexia and 2) 153,728 age-matched women from the general population. Cumulative incidences were estimated using competing risk models.
resultsWe followed 8516 women with cosmetic and 1823 with reconstructive implantation for a median of 17.3 and 17.4 years, respectively. Five BIA-ALCL cases were identified. The incidence rate of BIA-ALCL among women with textured cosmetic implants was 2.83 per 100,000 person-years (95% CI, 0.77-7.26), and for the reconstructive cohort, 3.44 per 100,000 person-years (95% CI, 0.09-19.16). No statistically significant differences were found across indications or implant texturing types, and almost all implant brands on the market were involved. The incidence of other lymphomas after cosmetic implantation resembled that of the control cohorts. No BIA-SCC cases were identified.
conclusionsThis study provides a population-based estimate of BIA-ALCL incidence, more precise and higher than most previous studies. No textured implants are without risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.